TABLE 2.

Interpretive agreement between results of fluconazole disk diffusion tests and standard 48-h BMDa

Organism (no. tested)Test methodd% of results in each categoryb% Agreementc% errors
SSDDRVMEMEM
C. albicans (1,631)Ref.-MIC99.80.20.0
Ref.-disk99.50.40.199.60.00.10.3
Part.-disk97.60.71.797.70.01.40.9
C. glabrata (403)Ref.-MIC69.526.34.2
Ref.-disk93.62.24.271.70.80.527.0
Part.-disk71.514.414.160.60.77.431.3
C. parapsilosis (400)Ref.-MIC93.36.20.5
Ref.-disk91.03.06.093.30.01.05.7
Part.-disk85.54.010.585.50.04.89.7
C. tropicalis (327)Ref.-MIC99.10.30.6
Ref.-disk98.80.60.697.90.60.60.9
Part.-disk89.67.03.488.70.63.47.3
All Candida spp. (2,949)Ref.-MIC91.66.71.7
Ref.-disk94.12.23.792.80.20.46.6
Part.-disk87.94.57.687.40.23.39.1
  • a Fluconazole disk diffusion testing was performed according to NCCLS method M44-A, and fluconazole BMD MIC testing was performed according to NCCLS method M27-A2.

  • b Fluconazole susceptibility categories: S, susceptible, MIC of ≤8 μg/ml (≥19 mm); SDD, susceptible dose dependent, MIC of 16 to 32 μg/ml (15 to 18 mm); R, resistant, MIC of ≥64 μg/ml (≤14 mm).

  • c Percent categorical agreement between disk diffusion and MIC test results.

  • d Ref.-MIC, MIC testing performed by ARTEMIS reference laboratory; Ref.-disk, disk testing performed by ARTEMIS reference laboratory; Part.-disk, disk testing performed by ARTEMIS participants.